Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge
Executive Summary
Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.